Combined drug brain uptake and drug brain metabolism model
| Reference number | |
| Coordinator | QUIXOLABS AB |
| Funding from Vinnova | SEK 500 000 |
| Project duration | July 2015 - July 2016 |
| Status | Completed |
Purpose and goal
In accordance with the goal a drug brain metabolism (DBM) model has been developed. The model is an extension of Quixolabs´ existing ex vivo model. The developed DBM model is useful for identifying metabolites formed in the brain and it is a direct add-on to current models. The model is now being commercialized. The goal to develop an advanced DBM model is party accomplished. Functional similarities of different CYPS and drug-drug interactions in mammals and locusts have been indicated. PoC MALDI-MSI has been performed and slicing technique is being transferred.
Expected results and effects
Unexpectedly, changes in the methodologies were needed. These changes and results from a thorough investigation of clozapine encouraged us to pursue new opportunities. This resulted in new models each creating value for the customers while taken together gives the full picture combining brain barrier penetration, efflux, metabolism, and analysis of the unbound fraction in intact brains. To verify the models several of known drugs have been tested and the findings correlate well with the data in the literature for mammals.
Planned approach and implementation
The ambitious goal was to develop two drug metabolism models, i.e. the basic model and the advanced model. The main focus was the basic model and this has been verified by a substantial amount of PoC data. To verify the assumptions, drug-drug interactions and functional species similarities were investigated. These studies gave raise to new opportunities that were pursued and translated into new models, providing significant value creation to our current models. Thus, not all initial goals were reached as new opportunities which added value to our current business were prioritized.